ReviewPediatric nephrology (Berlin, Germany)2010
FGF23 and the parathyroid glands.
Review in Pediatric nephrology (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 88 citations in OpenAlex.
- Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta.Journal of bone and mineral metabolism · 2011Trial
- Contractile myografts confer systemic anti-aging benefits.Nature aging · 2026Article
- Follicular Klotho in the Ovarian Microenvironment: Exploring Its Role in IVF Outcome Prediction.Medicina (Kaunas, Lithuania) · 2026Article
- Hypoparathyroidism: a brief historical overview for clinicians.Frontiers in endocrinology · 2026Review
- Ectopic Production of Parathyroid Hormone and Production of Parathyroid Hormone-related Protein in Dedifferentiated Endometrial Carcinoma Induced Severe Hypercalcemia.Internal medicine (Tokyo, Japan) · 2025Article
- Fibroblast growth factor 23 neutralizing antibody partially rescues bone loss and increases hematocrit in sickle cell disease mice.Scientific reports · 2025Article
- Relationship between uric acid to high-density cholesterol ratio (UHR) and circulating α-klotho: evidence from NHANES 2007-2016.Lipids in health and disease · 2024Article
- Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity.BMC pediatrics · 2024Observational
- Nephrocalcinosis tendency does not worsen under burosumab treatment for X-linked hypophosphatemic rickets: a multicenter pediatric study.Frontiers in pediatrics · 2024Article
- Expert consensus on multidisciplinary approach to the diagnosis and treatment of primary hyperparathyroidism in pregnancy in China.Endocrine · 2023Article
- New concepts in regulation and function of the FGF23.Clinical and experimental medicine · 2023Review
- Plasma S-Klotho level affects the risk of hyperuricemia in the middle-aged and elderly people.European journal of medical research · 2022Article
- Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).The Journal of clinical endocrinology and metabolism · 2022Article
- Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Association between serum uric acid and α-klotho protein levels in the middle-aged population.Aging · 2022Article
- The osteocyte as a signaling cell.Physiological reviews · 2022Review
- Clinical factors associated with severe hypophosphataemia after kidney transplant.BMC nephrology · 2021Observational
- Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management.Cureus · 2021Review
- Glymphatic Dysfunction in Patients With End-Stage Renal Disease.Frontiers in neurology · 2021Article
- Murine Fetal Serum Phosphorus is Set Independent of FGF23 and PTH, Except in the Presence of Maternal Phosphate Loading.Endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblast growth factor 23 (FGF23) is a phosphatonin that is secreted by osteocytes and osteoblasts in response to hyperphosphatemia and 1,25-dihydroxyvitamin D (1,25D). It acts on its receptor complex, Klotho-FGFR1c (fibroblast growth factor receptor 1 c-splicing form), in the distal convoluted tubule to repress renal phosphorus reabsorption in the proximal tubule and suppress the renal synthesis of 1,25D. Klotho-FGFR1c is also expressed in the parathyroid glands. FGF23 acts on the receptor complex in the parathyroid glands to decrease parathyroid hormone (PTH) gene expression and PTH secretion through activation of the MAPK pathway. In chronic kidney disease (CKD), both FGF23 and PTH are increased, implying resistance of the parathyroid glands to FGF23. There is a decrease in the Klotho-FGFR1c complex in the parathyroid glands in both experimental CKD and in patients with end-stage renal disease. In addition, in advanced experimental CKD, FGF23 has a decreased ability to inhibit PTH expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.